Highlights of This Issue 2503

SPECIAL FEATURES

CCR Translations

2505  Minimal Residual Disease in Breast Cancer: In Blood Veritas
Giulia Siravegna and Alberto Bardelli
See related article, p. 2643

Molecular Pathways

2508  Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson

2516  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

CCR Focus

2524  The Language of Pharmacodynamics
Susan E. Bates

2525  Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
William Douglas Figg and David R. Newell

2530  Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
Daniel L. Hertz and Howard L. McLeod

2541  Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo

2553  Circulating Tumor Cells: A Multifunctional Biomarker
Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

HUMAN CANCER BIOLOGY

2595  FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

2607  Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Uday S. Kammula

2617  miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Xuan Yu Chen, Xuegang Wang, Anming Ruan, Weiwai Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

2631  Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c-Sox2–Negative Feedback Loop Mechanism
Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
### CANCER THERAPY: PRECLINICAL

**2643** Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

See related article, p. 2505

**2651** Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He, and Annie L.M. Cheung

**2663** COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Anne-Sophie Gallouet, Marion Travert, Laurence Bresson-Bepoldin, Fabien Guilloton, Céline Pangault, Sylvie Caulet-Maugendre, Thierry Lamy, Karin Tarte, and Thierry Guillaudeux

**2674** Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth
Yansheng Hao, Bjorn Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, and Margaret A. Shipp

**2684** Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmilling, Weihua Xie, Janet Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson, and Duane A. Mitchell

**2695** Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

**2703** ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, and Olaf van Tellingen

**2714** Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Li Li, Rui Han, Hualiang Xiao, Caifu Lin, Yubo Wang, Hao Liu, Kulmin Li, Hengyi Chen, Fenfen Sun, Zhengzhou Yang, Jianxin Jiang, and Yong He

**2727** Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Diane Palmieri, Renata Duchnowska, Stephan Woditschka, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Soniska-Miekarek, Brunilde Grill, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jacek Jaszewski, and Patricia S. Steeg

**2740** Biologic Effects of Platelet-Derived Growth Factor Receptor β Blockade in Uterine Cancer
Ju-Won Roh, Jie Huang, Wei Hu, Xiaoyun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanaprprapar, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, and Anil K. Sood

**Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain**

**ABC1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy**
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, and Olaf van Tellingen

**Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal**
Li Li, Rui Han, Hualiang Xiao, Caifu Lin, Yubo Wang, Hao Liu, Kulmin Li, Hengyi Chen, Fenfen Sun, Zhengzhou Yang, Jianxin Jiang, and Yong He

**Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner**
Diane Palmieri, Renata Duchnowska, Stephan Woditschka, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Soniska-Miekarek, Brunilde Grill, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jacek Jaszewski, and Patricia S. Steeg

**Biologic Effects of Platelet-Derived Growth Factor Receptor β Blockade in Uterine Cancer**
Ju-Won Roh, Jie Huang, Wei Hu, Xiaoyun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanaprprapar, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, and Anil K. Sood
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2761</td>
<td>A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response</td>
<td>Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas</td>
</tr>
<tr>
<td>2773</td>
<td>In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas</td>
<td>Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm</td>
</tr>
<tr>
<td>2793</td>
<td>A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases</td>
<td>Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credl, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga</td>
</tr>
<tr>
<td>2805</td>
<td>Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff</td>
<td>Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Moigan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhukowicz, Piotr J. Wysoki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinuk, Jolanta Zok, Michal Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2805</td>
<td>Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff</td>
<td>Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Moigan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arhukowicz, Piotr J. Wysoki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinuk, Jolanta Zok, Michal Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.